Zydus gets USFDA nod for generic version of anti-epilepsy drug

Eligible for 180 days shared exclusivity for Brivaracetam tablets.

Eligible for 180 days shared exclusivity for Brivaracetam tablets.

Drugmaker Zydus Lifesciences has received the United States Food and Drug Administration (USFDA) approval to market Brivaracetam tablets. 

An antiepileptic drug, the approved product is a generic of multinational pharma firm UCB’s Briviact. “U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received the final approval from the USFDA to market Brivaracetam Tablets USP 10mg, 25mg, 50mg 75mg and 100mg,“ Zydus said in a statement on October 6.

Since it was “one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Brivaracetam Tablets USP 10mg, 25mg, 50mg, 75mg and 100mg, it is eligible for 180 days of shared generic drug exclusivity,” it said. 

Zydus gets USFDA approval for generic drug

The approved drug had annual sales of $412 million in the U.S., the company said citing IQVIA numbers. Brivaracetam is indicated for the treatment of partial-onset seizures in patients four years of age and older. 

“The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad,” Zydus said. 

Source link

Denial of responsibility! newsnaveen.online is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – admin@newsnaveen.com. The content will be deleted within 24 hours.

Similar Articles

Popular post